MIRA reports preclinical data for SKNY-1: biased CB1 modulation, CB2 activity, selective MAO-B inhibition

MIRA PHARMACEUTICALS, INC.

SKNY-1 shows biased CB1 antagonism: blocks β-arrestin (cravings) but spares G-protein (mood stability), unlike rimonabant.
Partial agonist at CB2 receptor, targeting metabolic regulation and inflammation for obesity comorbidities.
Selective MAO-B inhibition; no MAO-A or D1/D2/D3 dopamine receptor activity, supporting CNS safety.
Data from Eurofins in vitro studies; in vivo animal models for weight loss and nicotine addiction are being finalized.
Acquisition of SKNY by MIRA remains subject to regulatory and shareholder approval.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.